TY - JOUR
T1 - Effect of rebleeding on the course and incidence of vasospasm after subarachnoid hemorrhage
AU - Lord, A. S.
AU - Fernandez, L.
AU - Schmidt, J. M.
AU - Mayer, S. A.
AU - Claassen, J.
AU - Lee, K.
AU - Connolly, E. S.
AU - Badjatia, N.
N1 - Funding Information:
Dr. Lord and Dr. Fernandez report no disclosures. Dr. Schmidt has received research support from the NIH/NCRR. Dr. Mayer serves on scientific advisory boards for Edge Therapeutics, Inc., Orsan Medical Technologies Ltd., and Actelion Pharmaceuticals Ltd; has received speaker honoraria from Medivance and Astellas Pharma Inc.; receives publishing royalties for On Call: Neurology (WB Saunders, 2011), Neurological and Neurosurgical Intensive Care (Lippincott Williams & Wilkins, 2011), and Therapeutic Hypothermia (Marcel Dekker, 2010); serves as a consultant for Actelion Pharmaceuticals Ltd. and sanofi-aventis; and receives research support from the NIH and the Dana Foundation. Dr. Claassen reports no disclosures. Dr. Lee has served on scientific advisory boards for The Medicines Company and Baxter International Inc.; serves on speakers' bureaus for Baxter International Inc., UCB, Boehringer Ingelheim, The Medicines Company, and EKR Therapeutics Inc.; and has received research support from The Medicines Company. Dr. Connolly serves as a Section Editor for Neurosurgery and on the editorial boards of the Journal of Neurosurgery and World Neurosurgery; holds patent(s) re: Role of P-selectin and Complement in Stroke; receives publishing royalties for Handbook of Neurosurgery (Thieme, 2010); and receives research support from the FDA/NIH. Dr. Badjatia has received research support from the NIH/NCRR.
Funding Information:
Study funding: Supported by the NIH/NCRR and the NIH Roadmap for Medical Research (UL1-RR024156 to N.B. and KL2-RR024157 to J.M.S.). Information on NCRR is available at http://www.ncrr.nih.gov/ . Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp .
PY - 2012/1/3
Y1 - 2012/1/3
N2 - Objective: Rebleeding of an aneurysm is a leading cause of morbidity and mortality after subarachnoid hemorrhage (SAH). Whereas numerous studies have demonstrated the risk factors associated with rebleeding, few data on complications of rebleeding, including its effect on the development of delayed cerebral ischemia (DCI), are available. Methods: A nested case-control study was performed on patients with rebleeding and control subjects matched for modified Fisher scale, Hunt-Hess grade, age, and sex previously entered into a prospective database. Rebleeding was defined as new hemorrhage apparent on repeat CT with or without new symptoms. Incidence and time course of DCI and hospital complications were compared. A secondary analysis of DCI and hospital complications was also performed on subjects surviving to postbleed day 7. Results: We identified 120 patients with rebleeding and 359 control subjects from 1996 to 2011. The rebleeding rate was 8.6%. In both the primary and secondary analyses, there was no difference in the incidence of DCI or its time course (29% vs 27%, p = 0.6; 7 ± 5 vs 7 ± 6 days, p = 0.9 for primary analysis; 39% vs 31%, p = 0.1, 7 ± 5 vs 7 ± 6 days, p = 0.6 for the secondary analysis). In a multivariate logistic regression model, rebleeding was associated with the complications of hyponatremia, respiratory failure, and hydrocephalus. Patients with rebleeding had higher rates of mortality, brain death, and poor outcomes. Conclusions: Rebleeding after SAH is associated with multiple medical and neurologic complications, resulting in higher morbidity and mortality, but is not associated with change of incidence or timing of DCI.
AB - Objective: Rebleeding of an aneurysm is a leading cause of morbidity and mortality after subarachnoid hemorrhage (SAH). Whereas numerous studies have demonstrated the risk factors associated with rebleeding, few data on complications of rebleeding, including its effect on the development of delayed cerebral ischemia (DCI), are available. Methods: A nested case-control study was performed on patients with rebleeding and control subjects matched for modified Fisher scale, Hunt-Hess grade, age, and sex previously entered into a prospective database. Rebleeding was defined as new hemorrhage apparent on repeat CT with or without new symptoms. Incidence and time course of DCI and hospital complications were compared. A secondary analysis of DCI and hospital complications was also performed on subjects surviving to postbleed day 7. Results: We identified 120 patients with rebleeding and 359 control subjects from 1996 to 2011. The rebleeding rate was 8.6%. In both the primary and secondary analyses, there was no difference in the incidence of DCI or its time course (29% vs 27%, p = 0.6; 7 ± 5 vs 7 ± 6 days, p = 0.9 for primary analysis; 39% vs 31%, p = 0.1, 7 ± 5 vs 7 ± 6 days, p = 0.6 for the secondary analysis). In a multivariate logistic regression model, rebleeding was associated with the complications of hyponatremia, respiratory failure, and hydrocephalus. Patients with rebleeding had higher rates of mortality, brain death, and poor outcomes. Conclusions: Rebleeding after SAH is associated with multiple medical and neurologic complications, resulting in higher morbidity and mortality, but is not associated with change of incidence or timing of DCI.
UR - http://www.scopus.com/inward/record.url?scp=84863245933&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e31823ed0a4
DO - 10.1212/WNL.0b013e31823ed0a4
M3 - Article
C2 - 22170890
AN - SCOPUS:84863245933
SN - 0028-3878
VL - 78
SP - 31
EP - 37
JO - Neurology
JF - Neurology
IS - 1
ER -